| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Armata Pharmaceuticals, Inc.$4.26
-0.57 (-11.8%)
D 29Pipeline Score Richly Valued Biotech · Clinical
Market Cap
306.90 M
EPS
-7.76
P/E Ratio
-
Value Trade
241.49 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
6.11 M
Operating CF
-5.78 M
Total Assets
69.80 M
Total Liabilities
381.39 M
Equity
-311.59 M
D/E Ratio
12,345
1.95 %
Week
-44.19 %
1 Month
0 %
3 Month
18.41 %
6 Month
84.56 %
5 Year
-100 %
All Time
Cash Data
Cash Position
4.75 M
Monthly Burn
1.93 M
Runway
0.8 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
244.74 K
52 Week Range
1.74 - 16.34
% held by Insiders
68.55 %
% held by Institutions
10.7 %
Enterprise Value
675.82 M
Total Shares
36.70 M
Short %
2.18 %
Float Shares
20.26 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Armata Pharmaceuticals, Inc.
586Total events
1Upcoming
110Tier-1 (high impact)
2004 – 2026Coverage
Upcoming catalysts 1
Event history 585
Q3 2026
◆Trial InitiationSA02Trial
Plan to initiate Phase 3 superiority study of intravenous AP-SA02 in complicated SAB
complicated Staphylococcus aureus bacteremiasource ↗
May 13, 2026
▲QIDPSA02Designation
FDA granted QIDP designation for AP-SA02
complicated Staphylococcus aureus bacteremiasource ↗
May 13, 2026
▲Fast Track DesignationSA02Designation
FDA granted Fast Track designation for AP-SA02
complicated Staphylococcus aureus bacteremiasource ↗
May 13, 2026
▲Debt Royalty FinancingCorporate
Entered into secured credit agreement with Innoviva for $25 million maturing in 2029
May 7, 2026
▲Fast Track DesignationSA02Designation
FDA grants Fast Track Designation for AP-SA02
complicated bacteremia caused by methicillin-sensitive Staphylococcus aureus (MSSA) or methicillin-resistant Staphylococcus aureus (MRSA)source ↗
May 4, 2026
●PublicationPA02Presentation
Structural biology publication on phage P7-1 in Communications Biology
chronic respiratory infections due to Pseudomonas aeruginosa in cystic fibrosis and non-cystic fibrosis bronchiectasissource ↗
Q2 2026
◆Trial InitiationSA02Trial
Phase 3 superiority study initiation planned for AP-SA02
complicated bacteremia caused by Staphylococcus aureussource ↗
Mar 25, 2026
Mar 19, 2026
▲End Of Phase 2 MeetingSA02FDA Meeting
End-of-Phase 2 meeting with FDA for AP-SA02
complicated S. aureus bacteremiasource ↗
Drug Pipeline Intelligence
D29
Pipeline Score $10M
Pipeline ValueRichly Valued
Valuation Signal7
Drugs Scored0.0x
rNPV / MCap Top 33%
Micro Cap (rank 611 of 911)
Percentile RankArmata Pharmaceuticals, Inc. faces pipeline headwinds (29/100), with $1.2B risk-adjusted pipeline value, led by AP-SA02 in Bacteremia (Phase 1), across $74B in total addressable markets, but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AP-SA02 Monoclonal antibody | Bacteremia | Phase 1 | NCT05184764 | 13% | $382M | COMPLETED | 56 | - | - | Jan 14, 2025 | - | Mar 23, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
AP-SA02 Fast Track | Staphylococcus aureus bacteremia | Phase 2a | 2025-10-22 | enrollment: 42; AP SA02 group: randomized 29, clinical response day 12 88% (21/24); placebo group: randomized 13, clinical response day 12 58% (7/12); p value: 0.047; non response relapse AP SA02: 0% Read More | Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™ Read More | |
AP-SA02 Fast Track | Staphylococcus aureus bacteremia | Phase 2a | 2025-10-22 | enrollment: 42; AP SA02 group: randomized 29, clinical response day 12 88% (21/24); placebo group: randomized 13, clinical response day 12 58% (7/12); p value: 0.047; non response relapse AP SA02: 0% Read More | Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™ Read More | |
AP-SA02 Fast Track | Staphylococcus aureus bacteremia | Phase 2a | 2025-10-22 | enrollment: 42; AP SA02 group: randomized 29, clinical response day 12 88% (21/24); placebo group: randomized 13, clinical response day 12 58% (7/12); p value: 0.047; non response relapse AP SA02: 0% Read More | Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™ Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ARMP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ARMP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ARMPArmata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
Armata Pharmaceuticals has secured an additional $2.5 million in non-dilutive funding from the U.S. Department of Defense, bringing the total award to $28.7 million. This funding will support the Phase 3 readiness of their lead candidate, AP-SA02, aimed at treating complicated Staphylococcus aureus bacteremia. The company plans to initiate a Phase 3 study in the latter half of 2026.
Read more →ARMP▼ -7%on this news
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
Armata Pharmaceuticals reported its Q1 2026 financial results, highlighting progress in its lead therapeutic phage candidate AP-SA02, which is set to enter a Phase 3 study for complicated S. aureus bacteremia. The FDA has granted both QIDP and Fast Track Designation for this candidate. Despite these advancements, the company reported a significant net loss and a decrease in cash reserves.
Read more →ARMPArmata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
Armata Pharmaceuticals has received FDA Fast Track Designation for its product candidate AP-SA02, aimed at treating complicated bacteremia caused by Staphylococcus aureus. This designation allows for more frequent FDA interactions and a rolling review process, potentially expediting approval. The company plans to initiate a Phase 3 superiority study in late 2026, following positive results from earlier trials.
Read more →ARMP▲ +10.8%on this newsshared move
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
Armata Pharmaceuticals announced a publication in Communications Biology detailing the structure of phage P7-1, part of its AP-PA02 cocktail for treating Pseudomonas aeruginosa infections. The study highlights the phage's stability and infection mechanisms, contributing to the development of next-generation phage therapeutics. Armata's ongoing research aims to deepen the understanding of phage biology.
Read more →ARMP▼ -14.9%on this news
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors
Armata Pharmaceuticals has appointed Daniel B. Gilmer, Ph.D., to its Board of Directors, effective April 24, 2026. Dr. Gilmer, a seasoned executive with experience at Pfizer, will contribute his expertise in antimicrobial resistance and commercial strategy to advance Armata's bacteriophage therapeutics. His background includes leading the launch of PAXLOVID and involvement in various anti-infective initiatives.
Read more →ARMP▲ +8.6%on this news· ran to +19% by day 3
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
Armata Pharmaceuticals reported its financial results for Q4 and full-year 2025, showing a net loss of $124.3 million, primarily due to a significant impairment charge. The company recognized a decrease in grant revenue and research expenses, while general and administrative costs slightly increased. Despite these challenges, Armata continues to focus on developing bacteriophage therapeutics for antibiotic-resistant infections.
Read more →ARMPArmata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
Armata Pharmaceuticals announced a delay in reporting its fourth quarter and full-year 2025 financial results, which are now expected to be filed by March 31, 2026. Alongside this, the company highlighted positive developments regarding its AP-SA02 therapy, including successful results from a Phase 2a study and alignment with the FDA for future clinical trials. This positions Armata to initiate a Phase 3 superiority study later in the year, which could enhance treatment options for severe bacterial infections.
Read more →ARMP▲ +9.3%on this news· ran to +36% by day 1
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
Armata Pharmaceuticals has received FDA Qualified Infectious Disease Product (QIDP) designation for its multi-phage product candidate AP-SA02, aimed at treating complicated bacteremia caused by Staphylococcus aureus. This designation provides five years of market exclusivity and eligibility for fast track and priority review. The company plans to initiate a Phase 3 superiority study in late 2026.
Read more →ARMPArmata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated Staphylococcus aureus Bacteremia
Armata Pharmaceuticals has received FDA approval to advance its bacteriophage product candidate, AP-SA02, to a Phase 3 clinical study for treating complicated Staphylococcus aureus bacteremia. The FDA confirmed that data from the Phase 2a diSArm study supports this advancement. The Phase 3 study is expected to start in the second half of 2026, with a focus on demonstrating the superiority of AP-SA02 over existing treatments.
Read more →ARMPArmata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
Armata Pharmaceuticals will host a key opinion leader webinar on November 25, 2025, focusing on S. aureus bacteremia and its phage therapy candidate, AP-SA02. The event will feature Dr. Vance G. Fowler from Duke University, who will discuss the complexities of S. aureus infections and the implications of Armata's research. This follows positive findings from the diSArm study presented at IDWeek 2025.
Read more →ARMPArmata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
Armata Pharmaceuticals reported its third quarter 2025 results, highlighting promising efficacy data from its AP-SA02 study targeting Staphylococcus aureus infections. The company is preparing for late-stage clinical trials and has completed two Phase 2 trials. Financially, Armata's grant revenue has decreased, but it has improved operational efficiency and cash reserves.
Read more →ARMP▲ +7.4%on this newsshared move
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
Armata Pharmaceuticals has officially commissioned its new cGMP manufacturing facility in Los Angeles, enhancing its capability to produce bacteriophage therapeutics. The facility is crucial for advancing clinical trials, including a potential Phase 3 trial for its candidate AP-SA02 in 2026. This development underscores Armata's commitment to domestic manufacturing and addressing antibiotic resistance.
Read more →ARMPArmata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™
Armata Pharmaceuticals announced positive results from its Phase 2a diSArm study of AP-SA02, a bacteriophage cocktail for treating Staphylococcus aureus bacteremia. The study demonstrated significant clinical response rates and safety, leading to plans for a Phase 3 trial. The findings suggest AP-SA02 could become a new standard of care for this severe infection.
Read more →ARMPArmata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
Armata Pharmaceuticals will present late-breaking Phase 2a clinical data on its bacteriophage cocktail, AP-SA02, at IDWeek 2025. The presentation will focus on its efficacy and safety in treating complicated Staphylococcus aureus bacteremia. This study represents a significant milestone in phage therapy development, supported by a substantial Department of Defense grant.
Read more →ARMPCorporate Presentation Deborah Birx, M.D. Chief Executive Officer H.C. Wainwright 27 th Annual Global Investment Conference
Deborah Birx, M.D., the CEO of Armata Pharmaceuticals, presented at the H.C. Wainwright 27th Annual Global Investment Conference discussing forward-looking strategies and potential developments in bacteriophage therapies. The presentation highlighted the unique advantages of phages against antibiotic resistance and their potential to treat multi-drug resistant infections. However, various risks and uncertainties were also outlined, including funding challenges and uncertainties in clinical trial processes. Overall, the event showcased the company's vision in fighting against antimicrobial resistance through innovative therapeutic approaches.
Read more →ARMPArmata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
Armata Pharmaceuticals announced a publication in the Journal of Molecular Biology detailing the structure of phage Pa223, part of its AP-PA02 cocktail aimed at treating chronic respiratory infections. The study highlights advancements in cryogenic electron microscopy that enhance understanding of phage structure. AP-PA02 has shown promise in two Phase 2 trials, indicating potential for effective treatment.
Read more →ARMPArmata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Armata Pharmaceuticals will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025. CEO Deborah Birx will lead the corporate presentation on September 10, highlighting the company's focus on developing bacteriophage therapeutics for antibiotic-resistant infections. This participation underscores Armata's commitment to advancing its innovative therapies.
Read more →ARMPArmata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the
Armata Pharmaceuticals announced its second quarter 2025 results, highlighting a secured $15 million credit agreement with Innoviva and positive topline results from the Phase 1b/2a diSArm trial for AP-SA02. This data showcases evidence of phage therapy's efficacy in treating S. aureus bacteremia, with plans for a larger definitive efficacy study and a meeting with the FDA later in the year. Despite a reported operational loss and reduced cash reserves, Armata continues to advance its pipeline of bacteriophage therapeutics, aiming to tackle antibiotic-resistant infections and improve patient outcomes.
Read more →ARMP▲ +75.6%on this news
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
Armata Pharmaceuticals announced positive topline results from its Phase 1b/2a diSArm study of AP-SA02, a novel intravenous phage therapy for Staphylococcus aureus bacteremia. The trial met all primary endpoints, demonstrating improved clinical outcomes and safety compared to standard antibiotic therapy. Notably, 100% of subjects treated with AP-SA02 responded positively, with no serious adverse events reported.
Read more →ARMPArmata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
Armata Pharmaceuticals has announced its financial results for the first quarter of 2025, reporting a loss of $6.5 million, a significant decrease from $25.0 million in Q1 2024. The company completed its third Phase 2 study and anticipates topline data in the upcoming quarter, which may support future trials. Armata has received additional funding from the Department of Defense to further its AP-SA02 program, despite a decline in grant revenue. The firm continues to focus on developing bacteriophage therapeutics to address challenging bacterial infections.
Read more →ARMP▼ -15.4%on this news
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 Phase 1b/2a diSArm trial evaluated AP-SA02 as
Armata Pharmaceuticals has announced the receipt of an additional $4.65 million in non-dilutive funding from the U.S. Department of Defense to support its ongoing diSArm clinical trial of the bacteriophage therapeutic AP-SA02. This funding, enhancing a total of $26.2 million awarded to the company, will facilitate activities related to the Phase 2a study and preparation for discussions with the FDA. Topline data from the trial is expected in Q2 2025, which may pave the way for future pivotal studies focused on complicated Staphylococcus aureus bacteremia. The company's commitment to addressing antibiotic-resistant infections and improving treatment options remains steadfast.
Read more →ARMPArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update
Armata Pharmaceuticals reported its fourth quarter and full-year results for 2024, showing a significant clinical milestone with positive topline results from its Phase 2 Tailwind study for inhaled AP-PA02. The company has also completed enrollment in its Phase 1b/2a diSArm study and anticipates valuable data on the safety of AP-SA02. Despite an increase in losses from operations, Armata remains focused on developing bacteriophage therapeutics to combat antibiotic resistance, demonstrating commitment to future clinical trial designs.
Read more →ARMPArmata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva Proceeds to be used to continue to advance development of Armata's phage product candidates
Armata Pharmaceuticals has secured a $10 million credit agreement with Innoviva to support the development of its phage product candidates, including AP-PA02 and AP-SA02. This financing is particularly vital as it positions the company to advance its Phase 1b/2a trial for AP-SA02, planned for acute Staphylococcus aureus bacteremia. Additionally, Armata aims to prepare for an end-of-Phase 2 meeting with the FDA to discuss future clinical studies, while exploring further funding options, including non-dilutive sources. The agreement amends previous credit terms, extending their maturity dates to March 2026.
Read more →ARMP▼ -6.5%on this newsshared move
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a clinical-stage biotechnology company focused on the development of...
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced that Dr. Deborah Birx, the company’s CEO, will present at the 7th Annual Bacteriophage Therapy Summit in Boston, MA, on March 13, 2025. The event will showcase developments in bacteriophage therapeutics aimed at combating antibiotic-resistant bacterial infections. Armata is advancing its proprietary technology and pipeline of phage candidates for various pathogens including Pseudomonas aeruginosa and Staphylococcus aureus. This presentation accentuates Armata's commitment to advancing phage therapy as a viable treatment option.
Read more →ARMPArmata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tail wind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection Results demo
Armata Pharmaceuticals announced positive topline results from its Phase 2 Tailwind study, which evaluated the inhaled therapeutic AP-PA02 for chronic pulmonary Pseudomonas aeruginosa infections in non-cystic fibrosis bronchiectasis patients. The study indicated a statistically significant reduction in P.a. colony forming units compared to placebo, and demonstrated a favorable safety profile with mainly mild side effects. Overall, the findings suggest the potential of AP-PA02 as a viable treatment option, possibly reducing reliance on antibiotics.
Read more →ARMP▼ -11.6%on this news
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a clinical-stage biotechnology company focused on pathogen-specific...
Armata Pharmaceuticals, Inc. announced that Dr. Deborah Birx, the company's CEO, will deliver a presentation at the 5th Annual Phage Futures Annual Meeting in Boston, MA. This event is scheduled for November 19, 2024, at 1:15pm ET. Armata is a biotechnology company specializing in bacteriophage therapeutics aimed at treating antibiotic-resistant bacterial infections. The announcement highlights Armata's commitment to advancing its pipeline and expertise in phage therapy.
Read more →ARMPArmata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
Armata Pharmaceuticals reported its financial results for the third quarter of 2024, highlighting completed enrollment in significant clinical trials for its bacteriophage therapeutics. The company is set to release topline data from two Phase 2 studies by the end of the year and plans to initiate a pivotal Phase 3 study in 2025. While the company saw a reduction in net loss compared to the previous year, it continues to face challenges typical of clinical-stage biotechnology firms, relying on grant revenue for funding operations.
Read more →ARMP▲ +22.2%on this newsshared move
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia Topline data anticipated in Q1 20
Armata Pharmaceuticals has successfully completed enrollment for its Phase 1b/2a diSArm study, evaluating intravenous AP-SA02 for Staphylococcus aureus bacteremia. With 50 participants enrolled, topline data is expected in Q1 2025, which could lead to pivotal efficacy trials later that year. The study has demonstrated promising safety profiles at higher doses without significant adverse events, highlighting the potential of phage therapy. Armata is committed to advancing its therapies in response to the growing challenge of antibiotic resistance.
Read more →ARMPArmata Pharmaceuticals Announces Structural Biology Publication Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on the development of high-purity,...
Armata Pharmaceuticals has announced the publication of a study in Communications Biology detailing the structure of phage Pa193, a key candidate for their multi-phage anti-Pseudomonas therapies. This research enhances the understanding of phage structure, which may broaden their clinical application beyond Pseudomonas aeruginosa. The findings are expected to contribute valuable insights for developing bacteriophage therapeutics aimed at treating difficult bacterial infections. The publication aligns with Armata's commitment to advancing medicine through innovative phage therapy solutions.
Read more →ARMPArmata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on the development of high-purity,...
Armata Pharmaceuticals, Inc. announced that its CEO, Dr. Deborah Birx, will present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 11, 2024. The conference serves as an important opportunity for Armata to discuss its pathogen-specific bacteriophage therapeutics aimed at treating antibiotic-resistant bacterial infections. Their ongoing efforts in this field may attract investor interest, showcasing the company's commitment to tackling significant healthcare challenges.
Read more →ARMPPhase 2 Clinical Trials Evaluating Multi-phage Candidates for the Treatment of Adults with Bacteremia due to Staphylococcus aureus (diSArm) and Chronic Respiratory Infections due to Pseudomonas aeruginosa (SWARM-P.a. & T
Armata Pharmaceuticals has completed Phase 2 clinical trials for its phage candidates AP-SA02 and AP-PA02, focusing on treating bacteremia and bronchiectasis caused by resistant bacteria. Supported by a $21.6 million DoD grant, preliminary findings indicate that these treatments show promise in effectively reducing bacterial loads. Early results demonstrate that intravenous and inhaled phages are well tolerated by participants, with evidence suggesting certain patients may experience prolonged phage activity. Comprehensive data is anticipated by September 2024, potentially paving the way for pivotal Phase 3 trials in 2025.
Read more →ARMPArmata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on the development of high-purity,...
Armata Pharmaceuticals announced that Dr. Mina Pastagia will present at the 2024 Military Health System Research Symposium, discussing the company's two phage therapy programs targeting antibiotic-resistant infections. Currently, the intravenous AP-SA02 is 80% enrolled in its Phase 1b/2a study, supported by a significant Department of Defense grant. Preliminary results indicate promising safety and pharmacokinetics for both AP-SA02 and inhaled AP-PA02, setting the stage for pivotal Phase 3 trials next year.
Read more →ARMPArmata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer
Armata Pharmaceuticals has appointed David House as Senior Vice President of Finance and Principal Financial Officer, effective August 16, 2024. His extensive background in fiscal management within the life sciences sector is expected to strengthen the company's financial capabilities. House formerly held prominent roles, including Corporate Controller at ZO Skin Health. This strategic addition comes as Armata prepares to advance its bacteriophage therapeutic programs, demonstrating its commitment to developing solutions for antibiotic-resistant infections.
Read more →ARMP▲ +6.3%on this newsshared move
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update
Armata Pharmaceuticals announced its second quarter 2024 financial results and provided an update on its clinical programs. The company reported successful enrollment completion in its Phase 2 study for AP-PA02 and significant advancements in its AP-SA02 program. However, it also noted the lack of grant revenue for the quarter and an increase in operating losses compared to the previous year. The completion of a new manufacturing facility was also highlighted, which is expected to support further clinical trials and potential commercial production.
Read more →ARMPArmata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on the development of high-purity,...
Armata Pharmaceuticals has announced receipt of $5.25 million in non-dilutive funding from the U.S. Department of Defense. The funding will support the ongoing diSArm clinical trial, evaluating their optimized phage candidate AP-SA02 for treating complicated Staphylococcus aureus bacteremia. The study is currently 68% enrolled and aims to assess the safety and efficacy of AP-SA02 as an adjunct to standard antibiotic therapy. This initiative highlights Armata's commitment to addressing antibiotic-resistant bacterial infections.
Read more →ARMP▲ +11.9%on this news
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a clinical-stage biotechnology company focused on pathogen-specific...
Armata Pharmaceuticals has successfully completed enrollment for its Phase 2 Tailwind study evaluating inhaled AP-PA02 in non-cystic fibrosis bronchiectasis patients with chronic pulmonary Pseudomonas aeruginosa infection. The company expects to report topline data in the second half of 2024 and is planning a pivotal Phase 3 trial in 2025. This study aims to assess the safety and efficacy of phage therapy as both monotherapy and in combination with antibiotics. Positive insights gained from a previous study with cystic fibrosis patients have been integrated into this trial's design.
Read more →ARMP▲ +5.1%on this news· ran to +18% by day 1shared move
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024 Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a clinical-stage biotechnology company focused on the development of...
Armata Pharmaceuticals, Inc. announced its participation in the Viruses of Microbes 2024 conference, where it will present advancements in bacteriophage therapy. The presentation is scheduled for July 18, 2024, and will be led by Steven Branston, the Australia Site Head. This opportunity underscores Armata's focus on developing therapeutics targeting antibiotic-resistant infections through its proprietary technology.
Read more →ARMP▲ +13.9%on this news
Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update
Armata Pharmaceuticals reported its first quarter 2024 results, highlighting advancements in its clinical programs for bacteriophage therapeutics. The company is progressing towards pivotal studies expected in 2025 and has secured a $35 million investment from Innoviva to support these initiatives. Despite a significant net loss of $25 million, the company is bolstering its operational capacity with the nearing completion of a cGMP manufacturing facility. The financial outlook remains uncertain, hinging on the success of ongoing clinical trials and future product registrations.
Read more →ARMPArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
Armata Pharmaceuticals has reported its financial results for Q4 and full-year 2023, highlighting progress in developing pathogen-specific bacteriophage therapeutics. Notable advancements include positive trends in clinical trial enrollment for their AP-PA02 candidate and ongoing development of AP-SA02 for Staphylococcus aureus bacteremia, both of which show strong tolerability. The company has optimized its production capabilities to enhance phage purity, supporting future trails expected to begin in 2025. Despite a reported operating loss and decreased cash reserves, management remains optimistic about the company's direction and milestones ahead.
Read more →ARMPArmata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidate
Armata Pharmaceuticals has announced a $35 million secured credit agreement with Innoviva, which will be utilized to advance clinical trials for its phage-based therapeutic candidates, AP-PA02 and AP-SA02. This financing reflects Innoviva's confidence in Armata's development strategy and will support the ongoing Phase 2 trials as well as preparation for pivotal Phase 3 trials. The loan carries a 14.0% interest rate and is secured against company assets, which underscores potential financial obligations and risks associated with the agreement.
Read more →ARMPArmata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage...
Armata Pharmaceuticals, Inc. will present at the 6th Annual Bacteriophage Therapy Summit from February 27-29 in Boston. Dr. Mina Pastagia, Chief Medical Officer, is set to discuss Armata's clinical trials and ongoing development programs in bacteriophage therapeutics targeting antibiotic-resistant infections. The summit will focus on optimizing safety, efficacy, and manufacturing processes while fostering innovation through collaboration with phage experts.
Read more →ARMP▲ +8.9%on this news
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
Armata Pharmaceuticals reported positive developments in its third quarter 2023, emphasizing progress in its bacteriophage therapeutics pipeline with accelerated enrollment in key clinical studies. The company's financial results showed a revenue increase, supported by grant funding from the U.S. Department of Defense and a rise in cash reserves. However, operational losses increased compared to the previous year, with rising general and administrative costs. They are nearing the completion of a new manufacturing facility aimed at bolstering their capacity for late-stage trials and partnership opportunities.
Read more →ARMP▲ +10.2%on this news
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage...
Armata Pharmaceuticals announced that it will present topline data from its SWARM-P.a. clinical trial, which evaluates a novel inhaled therapeutic for Pseudomonas aeruginosa infections in cystic fibrosis patients, during the North American Cystic Fibrosis Conference. The presentation will take place on November 3, 2023. This follows positive topline data previously released in March 2023, indicating progress in developing bacteriophage-based therapies for difficult-to-treat bacterial infections. The conference aims to facilitate knowledge exchange among CF professionals globally.
Read more →ARMPArmata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023 Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata ), a clinical stage biotechnology company focused on pathogen-specific bacteriophage...
Armata Pharmaceuticals, Inc. has announced that its Chief Medical Officer, Dr. Mina Pastagia, will present an overview of their clinical trials at the upcoming Phage Futures: Global Digital Summit 2023. This virtual event, scheduled for October 25, aims to foster valuable discussions and partnerships in the field of bacteriophage therapeutics. Armata is dedicated to the development of solutions targeting antibiotic-resistant and difficult bacterial infections, with a strong pipeline of candidate therapies.
Read more →ARMPArmata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage...
Armata Pharmaceuticals has announced the dosing of the first patient in the Phase 2a portion of the diSArm study for AP-SA02, targeting Staphylococcus aureus bacteremia. This milestone follows positive safety and tolerability data from the completed Phase 1b trial. The study aims to assess the efficacy of AP-SA02 in conjunction with current antibiotic therapies, with support from the U.S. Department of Defense. Approximately 50 subjects will be enrolled in this next phase of the clinical trial.
Read more →ARMPArmata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata ), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for...
Armata Pharmaceuticals, Inc. announced that its CEO, Deborah Birx, will participate in a panel discussion at the Cantor Global Healthcare Conference in New York from September 26-28, 2023. This event highlights Armata's commitment to advancing its innovative bacteriophage therapeutics for antibiotic-resistant infections. The company's focus on both natural and synthetic phage candidates underlines its strategic direction in the biopharmaceutical sector.
Read more →ARMPArmata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update
Armata Pharmaceuticals reported its financial results for Q2 2023, highlighting advancements in two clinical studies for its bacteriophage therapies targeting antibiotic-resistant infections. The CEO announced ongoing trials for AP-PA02 and AP-SA02, with plans to initiate additional phases of development soon. Despite a loss from operations, the company is optimistic about its financial standing and the potential impact of its therapies. Looking ahead, Armata is preparing for more trials in the latter half of the year.
Read more →ARMPArmata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics Signs new $25 million credit agreement and extension of existing secured convertible credit agreemen
Armata Pharmaceuticals has announced a $25 million credit agreement aimed at advancing its bacteriophage therapeutic pipeline. This financing comes alongside a leadership transition, with Dr. Deborah L. Birx taking over as CEO. The funds will support the development of treatment candidates targeting antibiotic-resistant infections and assist in the completion of a state-of-the-art manufacturing facility. Additionally, the company amended an existing credit agreement, extending the maturity date to January 2025.
Read more →ARMPArmata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage...
Armata Pharmaceuticals announced an oral presentation regarding the Phase 1b/2a SWARM-P.a. clinical trial results at the 6th World Conference on Targeting Phage Therapy. The trial focused on evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of AP-PA02 in cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa infection. The study's positive topline data reinforces the potential of Armata's bacteriophage therapeutic approach in treating antibiotic-resistant infections.
Read more →ARMPArmata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update
Armata Pharmaceuticals announced its financial results for Q1 2023, highlighting positive developments in its clinical trials for bacteriophage therapies. The company reported encouraging topline results from the SWARM-P.a. Phase 1b/2a clinical trial and progressed in multiple studies for its therapeutic candidates AP-PA02 and AP-SA02. A $30 million convertible credit agreement was secured to further advance its research and manufacturing capabilities. However, the company noted an increase in operational losses and R&D expenditures compared to the prior year.
Read more →ARMP▲ +5.4%on this news
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update
Armata Pharmaceuticals announced its fourth quarter and full-year financial results for 2022, highlighting significant advancements in clinical trials and positive topline results from the SWARM-P.a. Phase 1b/2a study. CEO Dr. Brian Varnum emphasized the Company's commitment to phage therapy as an emerging treatment for antibiotic-resistant infections. Despite a net loss of $10.3 million in Q4 2022, Armata is positioned for further developments with expected grant funding and ongoing clinical trials for its lead programs AP-PA02 and AP-SA02. The results indicate a strategic approach towards advancing phage therapeutics in the competitive biotech landscape.
Read more →ARMP▲ +10.9%on this news
Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM- P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis AP-PA02 is well-tolerated and data supports progression to Phase 2b A
Armata Pharmaceuticals announced positive topline results from the Phase 1b/2a SWARM-P.a. clinical trial of inhaled AP-PA02 for cystic fibrosis patients. The treatment was found to be well-tolerated, and data indicated a significant reduction in bacterial load. Additionally, the first patient has been dosed in the Tailwind study of AP-PA02 for non-cystic fibrosis bronchiectasis. Results from these studies aim to provide supportive evidence for the efficacy of phage therapy against chronic infections.
Read more →ARMP▲ +25.4%on this news· ran to +45% by day 3
Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities
Armata Pharmaceuticals has announced the closure of a $30 million secured convertible credit agreement with Innoviva Strategic Opportunities. The funds from this agreement will be utilized to further develop its clinical candidates, AP-PA02 and AP-SA02, and to complete a biologics cGMP manufacturing facility. This manufacturing capability is expected to bolster Armata's ability to conduct late-stage clinical trials and form strategic partnerships in the future.
Read more →ARMP▼ -7%on this news· ran to -34% by day 3
Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage...
MARINA DEL REY, Calif. , Dec. 22, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infecti
Read more →ARMPArmata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage...
MARINA DEL REY, Calif. , Nov. 28, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infecti
Read more →ARMPArmata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update
Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update MARINA DEL REY, Calif., November 9, 2022 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriop
Read more →ARMPArmata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update
Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update MARINA DEL REY, Calif., August 11, 2022 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriop
Read more →ARMPArmata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage...
Second indication for AP-SA02 which targets Staphylococcus aureus including MRSA Potential to significantly improve PJI patient outcomes Expands Armata's pursuit of phage therapy as a solution for difficult-to-treat infections MARINA DEL REY, Calif. , August 01, 2022 /PRNewswi
Read more →ARMPArmata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage...
Study conducted in partnership with the US Department of Defense MARINA DEL REY, Calif. , May 23, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics
Read more →ARMP▼ -5%on this news· ran to +16% by day 3
Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage...
MARINA DEL REY, Calif , May 12, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infection
Read more →ARMP▼ -8.6%on this news
Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva
Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement MARINA DEL REY, Calif., March 31, 2022 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific
Read more →ARMP▲ +5.4%on this news· ran to +24% by day 1
Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage...
MARINA DEL REY, Calif. , March 17, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infect
Read more →ARMPArmata Pharmaceuticals Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage...
MARINA DEL REY, Calif. , Feb. 22, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infecti
Read more →ARMPArmata Pharmaceuticals to Participate in Two Upcoming Investor Conferences Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage...
MARINA DEL REY, Calif. , Feb. 17, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infecti
Read more →ARMPArmata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company's Bacteriophage Development
Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company's Bacteriophage Development MARINA DEL REY, Calif., February 9, 2022 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused
Read more →ARMP▲ +6.1%on this news
Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata, us, our, or the Company ), a biotechnology company focused on pathogen-specific...
MARINA DEL REY, Calif. , Jan. 5, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bact
Read more →ARMP▲ +6.1%on this news
Brian Varnum, Chief Executive Officer Steve Martin, Chief Financial Officer
Brian Varnum, Chief Executive Officer Steve Martin, Chief Financial Officer January 5, 2022 NYSE American: ARMP 2 Forward Looking Statements This presentation contains "forward - looking" statements that involve risks, uncertainties and assumptions . If the risks or uncertaintie
Read more →ARMPArmata Pharmaceuticals Provides Regulatory and Clinical Update Reflecting Sustained Progress Across Key Phage Therapeutic Development Programs Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata, us, our, or the Company ), a biotechnology company focused on pathogen-specific...
MARINA DEL REY, Calif. , Nov. 18, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bac
Read more →ARMPArmata Pharmaceuticals Announces Third Quarter Results and Provides General Corporate Update Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage...
MARINA DEL REY, Calif. , Nov. 10, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infecti
Read more →ARMPArmata Pharmaceuticals to Present at the 2021 World Antimicrobial Resistance Congress Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on precisely targeted bacteriophage...
MARINA DEL REY, Calif. , Nov. 4, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infecti
Read more →ARMPArmata Enters Lease to Build State-of-the-Art R&D and GMP Manufacturing Facility 56,000 square foot facility in Los Angeles enables a substantial increase in manufacturing scale and capacity to support Armata's advancing
Armata Enters Lease to Build State-of-the-Art R&D and GMP Manufacturing Facility 56,000 square foot facility in Los Angeles enables a substantial increase in manufacturing scale and capacity to support Armata's advancing pipeline MARINA DEL REY, California, November 02, 2021
Read more →ARMPCystic Fibrosis Foundation Makes Equity Investment in Armata Pharmaceuticals Funds to be used to further advance development of lead candidate AP-PA02, which is being evaluated in a Phase 1b/2a clinical trial in Pseudomo
Cystic Fibrosis Foundation Makes Equity Investment in Armata Pharmaceuticals Funds to be used to further advance development of lead candidate AP-PA02, which is being evaluated in a Phase 1b/2a clinical trial in Pseudomonas aeruginosa respiratory infections in Innoviva, a sig
Read more →ARMPArmata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage...
MARINA DEL REY, Calif. , Sept. 8, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infecti
Read more →ARMPArmata Pharmaceuticals Announces Second Quarter Results and Provides General Corporate Update Continues to advance AP-PA02 through Phase 1b/2a clinical trial as a potential treatment for cystic fibrosis patients with chr
Armata Pharmaceuticals Announces Second Quarter Results and Provides General Corporate Update Continues to advance AP-PA02 through Phase 1b/2a clinical trial as a potential treatment for cystic fibrosis patients with chronic Pseudomonas aeruginosa Announced that Todd R. Patr
Read more →ARMPArmata Pharmaceuticals Announces Chief Executive Officer Transition Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata, us, our, or the Company ), a biotechnology company focused on pathogen-specific...
MARINA DEL REY, Calif. , Aug. 2, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bact
Read more →ARMPArmata Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage...
MARINA DEL REY, Calif. , July 7, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infectio
Read more →ARMPArmata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update Company earns $750,000 milestone payment related to SWARM-P.a. Study
Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update Company earns $750,000 milestone payment related MARINA DEL REY, Calif., May 13, 2021 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnolo
Read more →ARMPArmata Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Results and Provides General Corporate Update Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage...
MARINA DEL REY, Calif. , March 18, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infect
Read more →ARMPArmata Pharmaceuticals Announces Closing of Second and Final Tranche of $20 Million Private Placement with Innoviva
Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $20 Million Private Placement with Innoviva MARINA DEL REY, California, March 17, 2021 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on
Read more →ARMPArmata Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage...
MARINA DEL REY, Calif. , March 16, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infect
Read more →ARMPArmata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Development Programs
Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Development Programs MARINA DEL REY, California, January 27, 2021 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology co
Read more →ARMPTodd Patrick, Chief Executive Officer Brian Varnum, President and Chief Development Officer Steve Martin, Chief Financial Officer
Todd Patrick, Chief Executive Officer Brian Varnum, President and Chief Development Officer Steve Martin, Chief Financial Officer January 6, 2021 NYSE American: ARMP 2 I This presentation contains "forward - looking" statements that involve risks, uncertainties and assumptions .
Read more →ARMPArmata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors Biogen Chief Accounting Officer adds significant financial leadership experience
Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors Biogen Chief Accounting Officer adds significant financial leadership experience MARINA DEL REY, California, December 9, 2020 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Arm
Read more →ARMPArmata Pharmaceuticals Announces Third Quarter 2020 Results and Provides General Corporate Update Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a clinical-stage biotechnology company focused on precisely targeted...
MARINA DEL REY, Calif. , Nov. 12, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat b
Read more →ARMPArmata Pharmaceuticals Issues Letter to Shareholders Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata ), a clinical-stage biotechnology company focused on precisely targeted bacteriophage...
MARINA DEL REY, Calif. , Oct. 29, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infectio
Read more →ARMPArmata Pharmaceuticals Appoints Mina Pastagia, MD, MS as Vice President of Clinical Development Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on precisely targeted bacteriophage...
MARINA DEL REY, Calif. , Oct. 26, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infect
Read more →ARMPArmata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on precisely targeted bacteriophage...
MARINA DEL REY, Calif. , Oct. 15, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infect
Read more →ARMPArmata Pharmaceuticals to Present at the Virtual 2020 World Antimicrobial Resistance Congress Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on precisely targeted bacteriophage...
MARINA DEL REY, Calif. , Sept. 29, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infec
Read more →ARMPArmata Pharmaceuticals Announces Participation in Upcoming Investor Conferences Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on precisely targeted bacteriophage...
MARINA DEL REY, Calif. , Sept. 11, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infec
Read more →ARMPArmata Pharmaceuticals Announces Second Quarter 2020 Results and Provides General Corporate Update Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a clinical-stage biotechnology company focused on precisely targeted...
MARINA DEL REY, Calif. , Aug. 13, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat b
Read more →ARMPArmata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections Non-dilutive funding to be used to advance th
Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat Bacteremia Infections Non-dilutive funding to be used to advance the company's second phage-based therapeutic candidate in a Phase
Read more →ARMPArmata Pharmaceuticals Announces First Quarter 2020 Results and Provides General Corporate Update Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a clinical-stage biotechnology company focused on precisely targeted...
MARINA DEL REY, Calif. , May 14, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announc
Read more →ARMPArmata Pharmaceuticals to Participate in the Maxim Group M-Vest Infectious Disease Virtual Conference: The Renaissance of the Anti-Infective Sector Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on precisely targeted bacteriophage...
MARINA DEL REY, Calif. , April 28, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that Brian
Read more →ARMPArmata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc. Funds to be used primarily to advance its lead Pseudomonas aeruginosa candidate, AP-PA02
Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Funds to be used primarily to advance its lead Pseudomonas aeruginosa candidate, AP-PA02 MARINA DEL REY, California, March 30, 2020 - Armata Pharmaceuticals
Read more →ARMPArmata Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Results and Provides General Corporate Update
Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Results and Provides General Corporate Update MARINA DEL REY, Calif., March 19, 2020 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company f
Read more →ARMPArmata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation Award to help fund a Phase 1/2 clinical trial of the company's Pseudomonas aeruginosa phage candidate,
Armata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation Award to help fund a Phase 1/2 clinical trial of the company's Pseudomonas aeruginosa phage candidate, AP-PA02, as a treatment for drug-resistant respiratory
Read more →ARMPArmata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc. - Armata withdraws its previously filed registration statement on Form S-1
Armata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc. - Armata withdraws its previously filed registration statement on Form S-1 MARINA DEL REY, Calif., Feb. 13, 2020 /PRNewswire/ -- Armat
Read more →ARMPArmata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata's Bacteriophage Development Programs MARINA DEL REY, Calif. and
Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata's Bacteriophage Development Programs MARINA DEL REY, Calif. and BRISBANE, Calif., Jan. 28, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("A
Read more →ARMPArmata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a clinical-stage biotechnology company focused on precisely targeted...
MARINA DEL REY, Calif. , Nov. 12, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announ
Read more →ARMPArmata Pharmaceuticals Announces Receipt of $1.3 million R&D Tax Incentive Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata ), a clinical-stage biotechnology company focused on precisely targeted bacteriophage...
MARINA DEL REY, Calif. , Oct. 21, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has r
Read more →ARMPArmata Pharmaceuticals Strengthens Clinical Team with Appointment of Dr. Heather Dale Jones as Medical Director Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata ), a clinical-stage biotechnology company focused on precisely targeted bacteriophage...
MARINA DEL REY, Calif. , Oct. 16, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the appointme
Read more →ARMPArmata Pharmaceuticals Expands Board of Directors with the Appointment of Research and Development Veteran Todd C. Peterson, Ph.D. MARINA DEL REY, Calif., October 10 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP)
Armata Pharmaceuticals Expands Board of Directors with the Appointment of Research and Development Veteran Todd MARINA DEL REY, Calif., October 10 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely ta
Read more →ARMPTodd Patrick, Chief Executive Officer Ladenburg Thalmann 2019 Healthcare Conference New York, NY
Todd Patrick, Chief Executive Officer Ladenburg Thalmann 2019 Healthcare Conference New York, NY September 24, 2019 NYSE American: ARMP 2 I This presentation contains "forward - looking" statements that involve risks, uncertainties and assumptions . If the risks or uncertainties
Read more →ARMPArmata Pharmaceuticals to Participate in the Ladenburg Thalmann 2019 Healthcare Conference Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics...
MARINA DEL REY, Calif. , Sept. 19, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that management will be
Read more →ARMPArmata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa Initial clinical emphasis on difficult-to-treat respiratory infections in cystic fibrosis patients
Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa Initial clinical emphasis on difficult-to-treat respiratory infections in cystic fibrosis patients MARINA DEL REY, Calif., September 12, 2019 -- Armata Pharmaceutic
Read more →ARMPArmata Pharmaceuticals Announces Second Quarter Results and Provides Corporate and Clinical Update Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a clinical-stage biotechnology company focused on precisely targeted...
MARINA DEL REY, Calif. , Aug. 14, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announ
Read more →ARMPArmata Pharmaceuticals to Provide Corporate Update at the 39th Annual Canaccord Genuity Growth Conference Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics...
MARINA DEL REY, Calif. , Aug. 1, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that Brian Varnum , PhD,
Read more →ARMPKey Opinion Leader Event Phage - Based Therapeutics for the Treatment of Antimicrobial - Resistant Infections
Key Opinion Leader Event Phage - Based Therapeutics for the Treatment of Antimicrobial - Resistant Infections June 26, 2019 New York, NY 2 I This presentation contains "forward - looking" statements that involve risks, uncertainties and assumptions . If the risks or uncertaintie
Read more →ARMPTodd Patrick, Chief Executive Officer Brian Varnum, President and Chief Development Officer Steve Martin, Chief Financial Officer As of
Todd Patrick, Chief Executive Officer Brian Varnum, President and Chief Development Officer Steve Martin, Chief Financial Officer As of June 24, 2019 NYSE American: ARMP 2 I This presentation contains "forward - looking" statements that involve risks, uncertainties and assumptio
Read more →ARMPArmata Pharmaceuticals to Host Key Opinion Leader Meeting on Bacteriophage-Based Therapeutics on June 26 in New York Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics...
MARINA DEL REY, Calif. , June 18, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it will host a Key
Read more →ARMPArmata Pharmaceuticals Strengthens Intellectual Property Portfolio with New Patent Allowances in Europe and Canada Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics...
MARINA DEL REY, Calif. , June 3, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company continue
Read more →ARMPArmata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics...
MARINA DEL REY, Calif , May 28, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the publication of a case
Read more →ARMPC3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc. Shares of the combined company to commence trading on the NYSE Americ
C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc. Shares of the combined company to commence trading on the NYSE American exchange under the new symbol "ARMP" on May 10, 2019
Read more →ARMPAmpliPhi Biosciences Corporation 3579 Valley Centre Drive, Suite 100 San Diego, CA 92130 AmpliPhi Biosciences Announces Stockholder Approval of Business Combination with C3J Therapeutics San Diego
AmpliPhi Biosciences Announces Stockholder Approval of Business Combination with C3J Therapeutics 8, 2019 - AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-r
Read more →ARMPAmpliPhi Biosciences / C3J Therapeutics Conference Call to Discuss Proposed Merger - Script
AmpliPhi Biosciences / C3J Therapeutics Conference Call to Discuss Proposed Merger January 14, 2019, 4:30 p.m. ET Speaker Dial-In Phone Number: 1-866-250-8117 Conference ID: 10127534 Introduction: Robert Uhl, Westwicke Thank you, operator. Good morning everyone and thank y
Read more →ARMPAdvancing bacteriophage therapeutics for patients with antibiotic - resistant infections
Advancing bacteriophage therapeutics for patients with antibiotic - resistant infections January 7, 2019 NYSE American: APHB Forward Looking Statement This presentation contains "forward - looking" statements that involve risks, uncertainties and assumptions . If the risks or un
Read more →ARMPAmpliPhi Biosciences and C3J Therapeutics Agree to Merge Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhi's extensive
Biosciences and C3J Therapeutics Agree to Merge Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhi's extensive phage library and Phase 1/2-ready asset with C3J's expertise in s
Read more →ARMPAmpliPhi Biosciences Announces Presentation of Positive Clinical Data From its Expanded Access Program for Serious S. aureus Infections at IDWeek 2018 Conference 13 patients with serious and life-threatening S. aureus in
AmpliPhi Biosciences Announces Presentation of Positive Clinical Data From its Expanded Access Program for Serious S. aureus Infections at IDWeek 2018 Conference 13 patients with serious and life-threatening S. aureus infections were treated with AB-SA01 at the Westmead Hospit
Read more →ARMPCompany Overview We are a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections. Phages hav
We are a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections. Phages have a powerful and highly selective mechanism of action that enables them to
Read more →ARMPAdvancing bacteriophage therapeutics for patients with antibiotic - resistant infections Company Overview
Advancing bacteriophage therapeutics for patients with antibiotic - resistant infections Company Overview September 5, 2018 NYSE American: APHB 2 This presentation contains "forward - looking" statements that involve risks, uncertainties and assumptions. If the risks or uncer ta
Read more →ARMPAmpliPhi Biosciences Corporation 3579 Valley Centre Drive, Suite 100 San Diego, CA 92130 AmpliPhi Biosciences Reports Second Quarter 2018 Financial Results and Business Highlights 19 patients at 7 hospitals, with serious
AmpliPhi Biosciences Reports Second Quarter 2018 Financial 9, 2018) - AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced fin
Read more →ARMPAmpliPhi Biosciences Corporation 3579 Valley Centre Drive, Suite 100 San Diego, CA 92130 AmpliPhi Biosciences Reports First Quarter 2018 Financial Results and Business Highlights Announced positive topline results for th
AmpliPhi Biosciences Reports First Quarter 2018 Financial Results and Business Highlights 15, 2018) - AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistan
Read more →ARMPSECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this " Agreement ") is dated as of
This Securities Purchase Agreement (this "Agreement") is dated as of March 20, 2018, between AmpliPhi Biosciences Corporation, a Washington corporation (the "Company"), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a "
Read more →ARMPAmpliPhi Biosciences Corporation 3579 Valley Centre Drive, Suite 100 San Diego, CA 92130 AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2017 Financial Results and Business Highlights Announced positive topline
Biosciences Reports Fourth Quarter and Full Year 2017 Financial Results and Business Highlights 14, 2018) - AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-res
Read more →ARMPAdvancing bacteriophage therapeutics for patients with antibiotic - resistant infections Biotech Showcase Conference
Advancing bacteriophage therapeutics for patients with antibiotic - resistant infections Biotech Showcase Conference January 8, 2018 NYSE American: APHB 2 This presentation contains "forward - looking" statements that involve risks, uncertainties and assumptions. If the risks or
Read more →ARMPAmpliPhi Biosciences Corporation 3579 Valley Centre Drive, Suite 100 San Diego, CA 92130 AmpliPhi Biosciences Provides Corporate and Strategic Update Under single-patient expanded access program, seven patients with seri
AmpliPhi Biosciences Provides Corporate and Strategic Update 14, 2017) - AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, t
Read more →ARMPAmpliPhi Biosciences Corporation 3579 Valley Centre Drive, Suite 100 San Diego, CA 92130 AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results and Business Highlights Six patients with life-threatening S. aur
AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results and Business Highlights 14, 2017) - AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections usin
Read more →ARMPAmpliPhi Biosciences Corporation 2016 Equity Incentive Plan Adopted by the Board of Directors
Biosciences Corporation Equity Incentive Plan by the Board of Directors: April 21, 2016 by the Shareholders: June 20, 2016 by the Board of Directors: June 14 and July 19, 2017 by the Shareholders: September 7, 2017 to and Continuation of Prior Plan. The Plan is intended as
Read more →ARMPAmpliPhi Biosciences Corporation 3579 Valley Centre Drive, Suite 100 San Diego, CA 92130 AmpliPhi Biosciences Reports Second Quarter 2017 Financial Results and Business Highlights - Continuing development of therapeutic
AmpliPhi Biosciences Reports Second Quarter 2017 Financial Results and Business Highlights Diego (August 14, 2017) - AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology,
Read more →ARMPAMPLIPHI BIOSCIENCES CORPORATION FIRST AMENDMENT TO COMMON STOCK ISSUANCE AGREEMENT This First Amendment to Common Stock Issuance Agreement (this " Amendment ") is made as of
BIOSCIENCES CORPORATION TO COMMON STOCK ISSUANCE AGREEMENT First Amendment to Common Stock Issuance Agreement (this "Amendment") is made as of June 27, 2017, by and among AmpliPhi Biosciences Corporation, a Washington corporation (the "Company"), and the persons and entities
Read more →ARMPDeveloping Bacteriophage Therapies for Patients with Antibiotic - Resistant Infections
Developing Bacteriophage Therapies for Patients with Antibiotic - Resistant Infections June 6, 2017 NYSE MKT: APHB 2 This presentation contains "forward - looking" statements that involve risks, uncertainties and assumptions. If the risks or uncer tainties materialize or the ass
Read more →ARMPAmpliPhi Biosciences Corporation 3579 Valley Centre Drive, Suite 100 San Diego, CA 92130 AmpliPhi Biosciences Reports First Quarter 2017 Financial Results and Provides Business Highlights Conference call begins at 4:30 p
AmpliPhi Biosciences Reports First Quarter 2017 Financial Results and Provides Business Highlights Conference call begins at 4:30 p.m. ET Diego (May 15, 2017) - AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the development of therapies for antibiotic-resista
Read more →ARMPAmpliPhi Biosciences Corporation 3579 Valley Centre Drive, Suite 100 San Diego, CA 92130 AmpliPhi Biosciences Announces Pricing of $10.4 Million Underwritten Public Offering of Common Stock and Common Warrants San Diego
AmpliPhi Biosciences Announces Pricing of $10.4 Million Underwritten Public Offering of Common Stock and Common Warrants Diego (May 4, 2017) - AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a biotechnology company focused on the development of therapies for drug-resistant
Read more →ARMPAmpliPhi Biosciences Corporation 3579 Valley Centre Drive, Suite 100 San Diego, CA 92130 AmpliPhi Biosciences Announces a New Strategic Emphasis on Personalized Therapies for Serious or Life-Threatening Antibiotic-Resist
AmpliPhi Biosciences Announces a New Strategic Emphasis on Personalized Therapies for Serious or Life-Threatening Antibiotic-Resistant Infections 1, 2017) - AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the field of bacteriophage technology, announces a new
Read more →ARMPAmpliPhi Biosciences Corporation Amendment to Offer Letter Agreement This Amendment to Offer Letter Agreement (this " Amendment ") is entered into by and between AmpliPhi Biosciences Corporation (the " Company ") and M.
Biosciences Corporation This Amendment to Offer Letter Agreement (this "Amendment") is entered into by and between AmpliPhi Biosciences Corporation (the "Company") and M. Scott Salka (hereinafter "Employee") effective as of April 1, 2017 (the "Effective Date"), and as of the
Read more →ARMPAmpliPhi Biosciences Corporation 3579 Valley Centre Drive, Suite 100 San Diego, CA 92130 AmpliPhi Biosciences Reports 2016 Fourth-Quarter and Full-Year Results and Provides Corporate Highlights Positive clinical data and
AmpliPhi Biosciences Reports 2016 Fourth-Quarter and Full-Year Results and Provides Corporate Highlights Positive clinical data and strengthened management team support continued development of novel therapies for antibiotic-resistant 27, 2017) - AmpliPhi Biosciences Corpor
Read more →ARMPGlobal Leader in Bacteriophage Development to Combat Infectious Diseases January 2017 NYSE MKT: APHB www.ampliphibio.com
Global Leader in Bacteriophage Development to Combat Infectious Diseases January 2017 NYSE MKT: APHB www.ampliphibio.com 2 Safe Harbor Statement This presentation contains "forward - looking" statements that involve risks, uncertainties and assumptions. If the risks or uncer tai
Read more →ARMPAmpliPhi Biosciences Announces Pricing of Public Offering of Common Stock and Warrants AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a biotechnology company focused on the discovery, development and commercialization
Biosciences Announces Pricing of Public Offering of AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics, today announced the pricing of an underwritten public offering
Read more →ARMPSETTLEMENT AGREEMENT This Settlement Agreement ("Agreement") by and between NRM VII Holdings I, LLC, a Virginia limited liability company ("NRM"), and AmpliPhi Biosciences Corporation, a Washington corporation ("AmpliPhi
SETTLEMENT AGREEMENT This Settlement Agreement ("Agreement") by and between NRM VII Holdings I, LLC, a Virginia limited liability company ("NRM"), and AmpliPhi Biosciences Corporation, a Washington corporation ("AmpliPhi), is made and entered as of November 12, 2016, with refe
Read more →ARMPAmendment to Consulting Agreement This Amendment to Consulting Agreement (the " Amendment ") is made as of
Amendment to Consulting Agreement (the "Amendment") is made as of September 27, 2016, by and between AmpliPhi Biosciences Corporation, a Washington corporation (the "Company"), and Wendy S. Johnson (the "Consultant"). Capitalized terms not otherwise defined herein shall have t
Read more →ARMPCompany Overview We are a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics. Phage therapeutics use bacteriophages, a family of viruses, to kill pathogenic bact
We are a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics. Phage therapeutics use bacteriophages, a family of viruses, to kill pathogenic bacteria. Phages have powerful and highly selective mechanisms of action that p
Read more →ARMPAmpliPhi Biosciences Reports Second Quarter 2016 Financial Results and Provides Corporate Update San Diego
AmpliPhi Biosciences Reports Second Quarter 2016 Financial Results and Provides Corporate Update August 15, 2016 - AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infec
Read more →ARMPAmpliPhi Biosciences Announces Pricing
AmpliPhi Biosciences Announces Pricing of Registered Direct Public Offering of Common Stock and Warrants SAN DIEGO - May 31, 2016 - AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat dru
Read more →ARMPAmpliPhi Biosciences Corporation 3579 Valley Centre Drive, Suite 100 San Diego, CA 92130 Press Release AmpliPhi Biosciences Reports First Quarter 2016 Financial Results and Provides Corporate Update San Diego
AmpliPhi Biosciences Corporation 3579 Valley Centre Drive, Suite 100 San Diego, CA 92130 Press Release AmpliPhi Biosciences Reports First Quarter 2016 Financial Results and Provides Corporate Update May 12, 2016 - AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global l
Read more →ARMPJulian Kirk c/o Third Security, LLC The Governor Tyler 1881 Grove Ave Radford, Virginia 24141
Via Electronic-Mail Delivery & Federal Express Delivery Bioscience Corporation Valley Centre Drive, Suite 100 write to inform you that effective immediately, I am resigning from the Board of Directors of AmpliPhi Biosciences Corporation ("AmpliPhi" or the "Company"). am res
Read more →ARMPAmpliPhi Biosciences Corporation 3579 Valley Centre Drive, Suite 100 San Diego, CA 92130 Press Release AmpliPhi Biosciences Reports Full-Year 2015 Financial Results San Diego
AmpliPhi Biosciences Corporation 3579 Valley Centre Drive, Suite 100 San Diego, CA 92130 Press Release AmpliPhi Biosciences Reports Full-Year 2015 Financial Results March 30, 2016 - AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in developing bacteriophage
Read more →ARMPSteve Martin Page 1 of 8
We are pleased to confirm our offer of employment with AmpliPhi Biosciences Corporation (the "Company"), in the position of Senior Vice President, Chief Financial Officer on the terms set forth in this letter agreement (the "Agreement"). Position. As Senior Vice President, Chi
Read more →ARMPA Global Leader in Bacteriophage Development to Combat Infectious Diseases January 2016 Statements in this presentation that are not statements of historical fact are forward - looking statements within the meaning of th
A Global Leader in Bacteriophage Development to Combat Infectious Diseases January 2016 Statements in this presentation that are not statements of historical fact are forward - looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Su
Read more →ARMPAmpliPhi Biosciences Corporation 800 East Leigh Street Richmond, Virginia 23219 Press Release AmpliPhi BioSciences Cleared to Submit Listing Application to NYSE MKT Company Announces One-for-Fifty Reverse Stock Split Sha
AmpliPhi Biosciences Corporation 800 East Leigh Street Richmond, Virginia 23219 Press Release AmpliPhi BioSciences Cleared to Submit Listing Application to NYSE MKT Announces One-for-Fifty Reverse Stock Split of Common Stock Will Begin Trading on a Split-Adjusted Basis on A
Read more →ARMPAmpliPhi BioSciences Corporation 800 East Leigh Street Richmond, VA 23219 Press Release AmpliPhi Provides Corporate Update and Reports First Quarter 2015 Financial Results San Diego and Richmond, VA, USA, Ljubljana, Slov
AmpliPhi BioSciences Corporation 800 East Leigh Street Richmond, VA 23219 Corporate Update and Reports First Quarter 2015 Financial Results San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, May 19 2015 - AmpliPhi BioSciences Corporation (OTCQB: APHB
Read more →ARMPAmpliPhi Biosciences Corporation 4870 Sadler Road Glen Allen, Virginia 23060 Press Release AmpliPhi Biosciences Announces M. Scott Salka as New CEO Biotechnology entrepreneur brings extensive business development and fun
AmpliPhi Biosciences Corporation 4870 Sadler Road Glen Allen, Virginia 23060 Press Release AmpliPhi Biosciences Announces M. Scott Biotechnology entrepreneur brings extensive business development and fundraising expertise to leading bacteriophage-based antibacterials compa
Read more →ARMPAmpliPhi Biosciences Corporation 4870 Sadler Road Glen Allen, Virginia 23060 Press Release AmpliPhi BioSciences Corporation Announces $13 Million Financing Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia
AmpliPhi BioSciences Corporation Announces $13 Million Financing VA, USA, Ljubljana, Slovenia, and Sydney, Australia, March 10, 2015 - AmpliPhi BioSciences Corporation, (OTCQB: APHB), a global leader in bacteriophage-based antibacterial therapies to treat drug resistant infect
Read more →ARMPAmpliPhi Provides Shareholder Update Bacteriophage-based Antibacterial Therapies to Treat Drug Resistant Infections Advancing towards Human Clinical Studies 2015 Uplisting to Major Exchange Expected Richmond, VA, USA, Lj
AmpliPhi Provides Shareholder Update Bacteriophage-based Antibacterial Therapies to Treat Drug Resistant Infections Advancing towards Human Clinical Studies 2015 Uplisting to Major Exchange Expected Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, January 05, 2
Read more →ARMPAmpliPhi Announces Departure of CEO Jeremy Curnock Cook, Ampliphi's Chairman, Named Interim CEO Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia
AmpliPhi Announces Departure of CEO Jeremy Curnock Cook, Ampliphi's Chairman, Named Interim CEO Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, September 19, 2014 - AmpliPhi BioSciences Corporation (OTC:APHB) ("AmpliPhi"), the leader in the discovery and devel
Read more →ARMPAmpliPhi Announces Appointment of New Board Member RICHMOND, VA, US, LJUBLJANA, SLOVENIA and SYDNEY, AUSTRALIA
Announces Appointment of New Board Member RICHMOND, VA, US, LJUBLJANA, SLOVENIA and SYDNEY, AUSTRALIA, May 22, 2014 - AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant inf
Read more →ARMPTARGETED GENETICS CORPORATION REPORTS THIRD QUARTER 2009
TARGETED GENETICS CORPORATION REPORTS THIRD QUARTER 2009 FINANCIAL RESULTS SEATTLE, Wash., November 16, 2009 Targeted Genetics Corporation (NASDAQ: TGEN) today announced its financial results for the third quarter ended September 30, 2009. For the quarter ended September 30, 2
Read more →ARMPInvestor and Media Contact: Stacie D. Byars 206.660.2588 sdbyars@comcast.net TARGETED GENETICS CORPORATION REPORTS FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS Conference Call Today at 5:00 p.m. ET Seattle, WA
Investor and Media Contact: TARGETED GENETICS CORPORATION REPORTS FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS Conference Call Today at 5:00 p.m. ET Seattle, WA March 31, 2009 Targeted Genetics Corporation (NASDAQ: TGEN) today announced its financial results for the four
Read more →ARMPUnassociated Document Targeted Genetics Realigns Product Development Priorities and Implements Cost Reduction Measures - Company Focuses on Clinical Development Path for LCA, HD and ALS - - Cuts Costs by Personnel Reduct
Genetics Realigns Product Development Priorities Implements Cost Reduction Measures Company Focuses on Clinical Development Path for LCA, HD and ALS - Cuts Costs by Personnel Reductions and Salary Deferrals and Reductions - Wash., December 2, 2008- Targeted Genetics Corporat
Read more →ARMPUnassociated Document Targeted Genetics' Board of Directors Appoints B.G. Susan Robinson, President and CEO, as Director - H. Stewart Parker Resigns from the Company's Board of Directors
Genetics' Board of Directors Appoints B.G. Susan Robinson, President and CEO, as H. Stewart Parker Resigns from the Company's Board of Directors - Wash., November 17, 2008- Targeted Genetics Corporation (NASDAQ:TGEN) today announced that its Board Directors appointed B.G. Sus
Read more →ARMPUnassociated Document Targeted Genetics Board of Directors Names B.G. Susan Robinson as President and CEO - H. Stewart Parker, President and Chief Executive Officer and Barrie J. Carter, PhD, Executive Vice President and
Genetics Board of Directors Names B.G. Susan Robinson as President and H. Stewart Parker, President and Chief Executive Officer and Barrie J. Carter, PhD, Executive Vice President and Chief Scientific Officer Step Down - Wash., November 10, 2008- Targeted Genetics Corporation
Read more →ARMPTARGETED GENETICS REPORTS THIRD QUARTER 2008 FINANCIAL RESULTS Conference Call Today at 5:00 p.m.
GENETICS REPORTS THIRD QUARTER 2008 FINANCIAL RESULTS Call Today at 5:00 p.m. ET Wash., November 5, 2008 Targeted Genetics Corporation (NASDAQ: TGEN) today announced its financial results for the third quarter ended September 30, 2008. The Company will conference call with a
Read more →ARMPUnassociated Document TARGETED GENETICS REPORTS SECOND QUARTER 2008 FINANCIAL RESULTS Conference Call Today at 10:30 a.m.
GENETICS REPORTS SECOND QUARTER 2008 FINANCIAL RESULTS Call Today at 10:30 a.m. ET Wash., August 6, 2008 - Targeted Genetics Corporation (NASDAQ: TGEN) today announced its financial results for the second quarter ended June 30, 2008. The Company will hold a conference call w
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Carolyn Wang WeissComm Partners WeissComm Partners 415.946.1072 415.946.1065 sdbyars@wcpglobal.com cbwang@wcpglobal.com TARGETED GENETICS REPORTS ADDITIONAL DATA FROM INFLAMMAT
Stacie D. Byars Carolyn Wang WeissComm Partners WeissComm Partners 415.946.1072 415.946.1065 sdbyars@wcpglobal.com cbwang@wcpglobal.com GENETICS REPORTS ADDITIONAL DATA FROM ARTHRITIS CLINICAL TRIAL Mass. and SEATTLE, Wash. 30, 2008- Targeted Genetics Corporation (Nasdaq: TGE
Read more →ARMPInvestor and Media Contact: Stacie D. Byars WeissComm Partners for Targeted Genetics 415.946.1072 sdbyars@wcpglobal.com TARGETED GENETICS REPORTS FIRST QUARTER 2008 FINANCIAL RESULTS -- Conference Call Today at 10:30 a.m
sdbyars@wcpglobal.com GENETICS REPORTS FIRST QUARTER 2008 FINANCIAL RESULTS Conference Call Today at 10:30 a.m. ET -- 2008 - Targeted Genetics Corporation (NASDAQ: TGEN) today announced its financial results for the first quarter ended March 31, 2008. The Company hold a conf
Read more →ARMPInvestor and Media Contact: Stacie D. Byars WeissComm Partners for Targeted Genetics 415.946.1072 sdbyars@wcpglobal.com TARGETED GENETICS REPORTS FOURTH QUARTER AND YEAR-END 2007 FINANCIAL RESULTS -- Conference Call Toda
sdbyars@wcpglobal.com GENETICS REPORTS FOURTH QUARTER AND YEAR-END 2007 FINANCIAL Conference Call Today at 10:30 a.m. ET -- 5, 2008 - Targeted Genetics Corporation (NASDAQ: TGEN) today announced its financial results for the fourth quarter and year ended December 31, 2007. C
Read more →ARMPInvestor and Media Contacts: Stacie D. Byars Carolyn Wang Director, Communications WeissComm Partners Targeted Genetics Corporation 415.225.5050 206.521.7392 TARGETED GENETICS REPORTS ON RECOMBINANT DNA ADVISORY COMMITTE
Stacie D. Byars Carolyn Wang Director, Communications WeissComm Partners Targeted Genetics Corporation 415.225.5050 206.521.7392 ON RECOMBINANT DNA ADVISORY COMMITTEE (RAC) ASSESSMENT OF ITS PHASE I/II FOR INFLAMMATORY ARTHRITIS Genetics Corporation (Nasdaq: TGEN) today repor
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation 206.521.7392 TARGETED GENETICS ANNOUNCES THAT FDA HAS REMOVED HOLD ON PHASE I/II CLINICAL TRIAL OF tgAAC94 FOR INFLAMMATO
Genetics Corporation GENETICS ANNOUNCES THAT FDA HAS REMOVED HOLD ON PHASE I/II CLINICAL TRIAL tgAAC94 FOR INFLAMMATORY ARTHRITIS II Clinical Trial Protocol Design Underway Genetics Corporation (Nasdaq: TGEN) today announced that the U.S. Food and Administration (FDA) remove
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation 206.521.7392 TARGETED GENETICS REPORTS THIRD QUARTER 2007 FINANCIAL RESULTS -- Conference Call Today at 10:30 a.m. ET --
Genetics Corporation GENETICS REPORTS THIRD QUARTER 2007 FINANCIAL RESULTS Conference Call Today at 10:30 a.m. ET -- October 31, 2007 - Targeted Genetics Corporation (NASDAQ: TGEN) today announced its financial results for the third quarter of 2007. third quarter of 2007, th
Read more →ARMPUnassociated Document Investor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation 206.521.7392 TARGETED GENETICS REPORTS SECOND QUARTER 2007 FINANCIAL RESULTS Seattle, WA
Genetics Corporation GENETICS REPORTS SECOND QUARTER 2007 FINANCIAL RESULTS 7, 2007 - Targeted Genetics Corporation (NASDAQ: TGEN) today announced its financial results for the second quarter of 2007. As previously announced, Company will hold a conference call with analysts
Read more →ARMPUnassociated Document [logo] Investor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS RESPONDS TO WASHINGTON POST ARTICLE Seattle, WA
Genetics Corporation GENETICS RESPONDS TO WASHINGTON POST ARTICLE 6, 2007 - Targeted Genetics Corporation (Nasdaq: TGEN) responded to an article in today's Washington Post with respect to its development program of tgAAC94, an investigational therapy for the treatment of infl
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS PROVIDES UPDATE ON INFLAMMATORY ARTHRITIS PHASE I/II TRIAL Seattle, WA
Genetics Corporation GENETICS PROVIDES UPDATE ON ARTHRITIS PHASE I/II TRIAL 26, 2007 - Targeted Genetics Corporation (Nasdaq: TGEN) provided an update on its development program of tgAAC94, an investigational therapy for the treatment of inflammatory arthritis. This Phase I/
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS' INFLAMMATORY ARTHRITIS PHASE I/II TRIAL PLACED ON CLINICAL HOLD Seattle, WA
Genetics Corporation GENETICS' INFLAMMATORY ARTHRITIS I/II TRIAL PLACED ON CLINICAL HOLD 24, 2007 - Targeted Genetics Corporation (Nasdaq: TGEN) announced that after recent discussions with the United States Food and Drug Administration (FDA), the development program of tgAA
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 660-2588 TARGETED GENETICS COMPLETES $19.5
Genetics Corporation GENETICS COMPLETES $19.5 MILLION Targeted Genetics Corporation (NASDAQ: TGEN) today announced the completion its private equity offering of 6.7 million shares of its common stock at a purchase price of $2.905 per share, together with warrants to purchase
Read more →ARMPTARGETED GENETICS ANNOUNCES $19.5
GENETICS ANNOUNCES $19.5 MILLION PRIVATE PLACEMENT OF COMMON STOCK WA, Jun 22, 2007 (MARKET WIRE via COMTEX News Network) -- Targeted Genetics Corporation (NASDAQ: TGEN) today announced that it has entered into definitive agreements with institutional and other accredited inve
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS REPORTS ADDITIONAL DATA FROM INFLAMMATORY ARTHRITIS CLINICAL TRIAL Seattle, WA
Genetics Corporation GENETICS REPORTS ADDITIONAL DATA FROM ARTHRITIS CLINICAL TRIAL 4, 2007 - Targeted Genetics Corporation (Nasdaq: TGEN) today announced additional data from the dose escalation arm of the ongoing Phase I/II clinical study of tgAAC94 in patients with inflam
Read more →ARMPlogo] Investor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS COMPLETES ENROLLMENT AND INITIAL DOSING OF tgAAC94 PHASE I/II TRIAL IN PATIENTS WI
Genetics Corporation GENETICS COMPLETES ENROLLMENT AND INITIAL DOSING OF tgAAC94 PHASE I/II TRIAL PATIENTS WITH INFLAMMATORY ARTHRITIS 24, 2007 - Targeted Genetics Corporation (Nasdaq: TGEN) today announced that has achieved its enrollment target of 120 patients in its ongoin
Read more →ARMPInvestor and Media Contacts: Marion Ferguson Celladon Corporation (858) 366-4288 Stacie D. Byars Targeted Genetics Corporation (206) 521-7392 CELLADON AND TARGETED GENETICS INITIATE PHASE I CLINICAL TRIAL OF MYDICAR IN P
AND TARGETED GENETICS INITIATE PHASE I CLINICAL TRIAL OF IN PATIENTS WITH HEART FAILURE Jolla, CA and Seattle, 17, 2007 - Celladon Corporation and Targeted Genetics Corporation (Nasdaq: today announced the initiation of a Phase I clinical trial of (AAV1/SERCA2a) in patients
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation 206.521.7392 TARGETED GENETICS REPORTS FIRST QUARTER 2007 FINANCIAL RESULTS Seattle, WA
Genetics Corporation GENETICS REPORTS FIRST QUARTER 2007 FINANCIAL RESULTS 2007 - Targeted Genetics Corporation (NASDAQ: TGEN) today announced its financial results for the first quarter of 2007. As previously announced, the Company will hold a conference call with analysts a
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS REPORTS FOURTH QUARTER AND YEAR-END 2006 FINANCIAL RESULTS -- Company reports $4.0 milli
Genetics Corporation GENETICS REPORTS FOURTH QUARTER AND 2006 FINANCIAL RESULTS Company reports $4.0 million in revenue for Q406, a 106% increase over the quarter a year ago and resulting in a net profit of $0.08 per share WA - March 29, 2006 - Genetics Corporation (NASDAQ:
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 PHASE I DATA FROM TARGETED GENETICS' tgAAC09 VACCINE FOR HIV/AIDS PRESENTED AT SCIENTIFIC CONFERENCE Seatt
Genetics Corporation I DATA FROM TARGETED GENETICS' tgAAC09 VACCINE FOR HIV/AIDS AT SCIENTIFIC CONFERENCE February 28, 2007 - Targeted Genetics Corporation (Nasdaq: TGEN) today announced that Dr. Jan van Lunzen, Medical Director, University Medical Center, Hamburg Eppendorf,
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS COMPLETES $8.7 MILLION IN PRIVATE EQUITY FINANCING Seattle, WA
Genetics Corporation GENETICS COMPLETES $8.7 MILLION IN PRIVATE EQUITY FINANCING 11, 2007 - Targeted Genetics Corporation (Nasdaq: TGEN) today announced the completion of its private equity offering of 2.18 million shares of Targeted Genetics' common stock, together with warr
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS ANNOUNCES $8.7 MILLION PRIVATE PLACEMENT Seattle, WA
Genetics Corporation GENETICS ANNOUNCES $8.7 MILLION PRIVATE PLACEMENT 8, 2007 - Targeted Genetics Corporation (Nasdaq: TGEN) today announced that has obtained agreement from select institutional investors to purchase in a private placement 2.18 million shares of Targeted Gen
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS LEVERAGES VALUE OF ITS AAV PATENT ESTATE IN LICENSING AGREEMENT WITH AMSTERDAM MOLECULAR
Genetics Corporation GENETICS LEVERAGES VALUE OF ITS AAV PATENT ESTATE IN LICENSING AGREEMENT AMSTERDAM MOLECULAR THERAPEUTICS license covers the use of Targeted Genetics' AAV1 technology the treatment of lipoprotein lipase deficiencies- December 12, 2006 - Targeted Genetics
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 INTERIM DATA ON USE OF tg AAC94 IN THE TREATMENT OF INFLAMMATORY ARTHRITIS PRESENTED
Genetics Corporation DATA ON USE OF tgAAC94 IN THE TREATMENT OF INFLAMMATORY AT THE AMERICAN COLLEGE OF RHEUMATOLOGY MEETING of safety at all dose levels and trend in sustained decrease signs and symptoms of disease in target joint - November 13, 2006 - Targeted Genetics Co
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS AND BIOGEN IDEC RESTRUCTURE DEBT Seattle, WA
Genetics Corporation GENETICS AND BIOGEN IDEC RESTRUCTURE DEBT November 7, 2006 - Targeted Genetics Corporation (Nasdaq: TGEN) announced that it has entered into a newly amended agreement with Biogen Idec, Inc. (Nasdaq: BIIB) to restructure repayment of $8.15 million of debt.
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 INTERIM DATA FROM TARGETED GENETICS' PHASE I HIV/AIDS VACCINE TRIAL TO BE PRESENTED
Genetics Corporation DATA FROM TARGETED GENETICS' PHASE I HIV/AIDS VACCINE TRIAL BE PRESENTED AT LEADING EUROPEAN AIDS VACCINE MEETING candidate well tolerated; modest immune response observed in a subset of and Seattle, WA - August 30, 2006 Targeted Genetics Corporation (Na
Read more →ARMPTARGETED GENETICS ENTERS INTO NEW AGREEMENT WITH THE INTERNATIONAL AIDS VACCINE INITIATIVE TO SUPPORT ITS ONGOING HIV/AIDS
GENETICS ENTERS INTO NEW AGREEMENT WITH INTERNATIONAL AIDS VACCINE INITIATIVE TO SUPPORT ITS HIV/AIDS VACCINE DEVELOPMENT PROGRAM 28, 2006 - Targeted Genetics Corporation (Nasdaq: TGEN) announced today that has entered into a collaboration and license agreement with the Inter
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS PRESENTS ENCOURAGING INTERIM DATA FROM AN ONGOING PHASE I/II TRIAL OF tgAAC94 IN PATIENT
Genetics Corporation GENETICS PRESENTS ENCOURAGING INTERIM DATA AN ONGOING PHASE I/II TRIAL OF tgAAC94 IN PATIENTS WITH INFLAMMATORY data show positive trends toward sustained improvement in signs and symptoms WA and Baltimore, MD 1, 2006 - Targeted Genetics Corporation (Nas
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics 206.521.7392 TARGETED GENETICS REPORTS FIRST QUARTER 2006 FINANCIAL RESULTS Seattle, WA
Investor and Media Contact: Director, Communications TARGETED GENETICS REPORTS FIRST QUARTER 2006 FINANCIAL RESULTS Seattle, WA May 2, 2006 Targeted Genetics Corporation (NASDAQ: TGEN) today announced its financial results for the first quarter of 2006. As previously announce
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 ZAMBIA BEGINS FIRST PREVENTIVE HIV VACCINE TRIAL Lusaka, Zambia and Seattle, Washington, USA
Investor and Media Contact: Director, Communications Targeted Genetics Corporation ZAMBIA BEGINS FIRST PREVENTIVE HIV VACCINE TRIAL Lusaka, Zambia and Seattle, Washington, USA April 26, 2006 The Zambia Emory HIV Research Project (ZEHRP), the International AIDS Vaccine Initia
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS AMENDS tgAAC94 CLINICAL PROTOCOL AND ADVANCES ONGOING TRIAL TO PHASE I/II STATUS Amendme
Investor and Media Contact: Director, Communications Targeted Genetics Corporation TARGETED GENETICS AMENDS tgAAC94 CLINICAL PROTOCOL AND ADVANCES ONGOING TRIAL TO PHASE I/II STATUS Amendment potentially accelerates clinical development of therapy Seattle, WA March 16, 2006
Read more →ARMPexv99w1 Investor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS COMPLETES $5.0 MILLION PUBLIC OFFERING OF COMMON STOCK Seattle, WA
Investor and Media Contact: Director, Communications Targeted Genetics Corporation TARGETED GENETICS COMPLETES $5.0 MILLION PUBLIC OFFERING OF COMMON STOCK WA March 14, 2006 Targeted Genetics Corporation (NASDAQ: TGEN) today announced that it has completed a public offering
Read more →ARMPStacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS ANNOUNCES $5.0 MILLION PUBLIC OFFERING OF COMMON STOCK Seattle, WA
Director, Communications Targeted Genetics Corporation TARGETED GENETICS ANNOUNCES $5.0 MILLION PUBLIC OFFERING OF COMMON STOCK Seattle, WA March 10, 2006 Targeted Genetics Corporation (Nasdaq: TGEN), today announced that it has obtained agreements from select institutional
Read more →ARMPexv99w1 Investor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS REPORTS FOURTH QUARTER AND YEAR-END 2005 FINANCIAL RESULTS Seattle, WA
Investor and Media Contact: Director, Communications Targeted Genetics Corporation TARGETED GENETICS REPORTS FOURTH QUARTER AND YEAR-END 2005 FINANCIAL RESULTS Seattle, WA March 9, 2006 Targeted Genetics Corporation (NASDAQ: TGEN) today announced its preliminary financial r
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS ANNOUNCES STRATEGIC RESTRUCTURING TO REDUCE EXPENSES AND ADVANCE LEAD INFLAMMATORY ARTHR
Investor and Media Contact: Director, Communications Targeted Genetics Corporation TARGETED GENETICS ANNOUNCES STRATEGIC RESTRUCTURING TO REDUCE EXPENSES AND ADVANCE LEAD INFLAMMATORY ARTHRITIS PRODUCT CANDIDATE Seattle, WA January 24, 2005 Targeted Genetics Corporation (Nas
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS APPOINTS DAVID J. POSTON AS CHIEF FINANCIAL OFFICER Seattle, WA
Investor and Media Contact: Director, Communications Targeted Genetics Corporation TARGETED GENETICS APPOINTS DAVID J. POSTON AS CHIEF FINANCIAL OFFICER Seattle, WA January 18, 2006 Targeted Genetics Corporation (Nasdaq: TGEN) announced today the appointment of David J. Post
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS NAMED AS SUBCONTRACTOR TO NIAID CONTRACT TO EXPAND AAV-BASED HIV V
Investor and Media Contact: Director, Communications Targeted Genetics Corporation TARGETED GENETICS NAMED AS SUBCONTRACTOR TO NIAID CONTRACT TO EXPAND AAV-BASED HIV VACCINE PROGRAM funding to total approximately $22 Million Contract provides funding mechanism to develop AA
Read more →ARMPIAVI Begins First Phase II Preventive HIV Vaccine Trial in South Africa to Test Targeted Genetics HIV Vaccine Candidate Seattle, WA and New York, NY
IAVI Begins First Phase II Preventive HIV Vaccine Trial in South Africa to Test Targeted Genetics HIV Vaccine Candidate Seattle, WA and New York, NY November 14, 2005 Targeted Genetics Corporation (NASDAQ: TGEN) and The International AIDS Vaccine Initiative (IAVI) today announ
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS PRESENTS ADDITIONAL DATA FROM ITS INFLAMMATORY ARTHRITIS PROGRAM AT THE 13th ANNUAL CONG
Investor and Media Contact: Director, Communications Targeted Genetics Corporation TARGETED GENETICS PRESENTS ADDITIONAL DATA FROM ITS INFLAMMATORY ARTHRITIS PROGRAM AT THE 13th ANNUAL CONGRESS OF THE EUROPEAN SOCIETY OF GENE THERAPY Results demonstrate safety and reduction
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS INITIATES NEXT CLINICAL TRIAL of tgAAC94 in
Investor and Media Contact: Director, Communications Targeted Genetics Corporation TARGETED GENETICS INITIATES NEXT CLINICAL TRIAL of tgAAC94 in INFLAMMATORY ARTHRITIS SEATTLE, WA October 11, 2005 Targeted Genetics Corporation (Nasdaq: TGEN) today announced the initiation o
Read more →ARMP(TARGETED GENETICS LOGO)(R) INVESTOR AND MEDIA CONTACT: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS RESTRUCTURES BIOGEN DEBT SEATTLE, WA
(TARGETED GENETICS LOGO)(R) INVESTOR AND MEDIA CONTACT: Director, Communications Targeted Genetics Corporation TARGETED GENETICS RESTRUCTURES BIOGEN DEBT SEATTLE, WA -- September 1, 2005 -- Targeted Genetics Corporation (Nasdaq: TGEN) announced that it has entered into an a
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS ANNOUNCES TODD E. SIMPSON TO STEP DOWN AS CHIEF FINANCIAL OFFICER David Poston to be nam
Investor and Media Contact: Director, Communications Targeted Genetics Corporation TARGETED GENETICS ANNOUNCES TODD E. SIMPSON TO STEP DOWN AS CHIEF FINANCIAL OFFICER David Poston to be named as Acting CFO Seattle, WA August 22, 2005 Targeted Genetics Corporation (Nasdaq: T
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS REPORTS SECOND QUARTER FINANCIAL RESULTS Seattle, WA
Investor and Media Contact: Director, Communications Targeted Genetics Corporation TARGETED GENETICS REPORTS SECOND QUARTER FINANCIAL RESULTS Seattle, WA July 28, 2005 Targeted Genetics Corporation (NASDAQ: TGEN) today announced its financial results for its second quarter e
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS ANNOUNCES PRELIMINARY RESULTS OF PHASE I CLINICAL TRIAL OF tgAAC94 IN PATIENTS WITH INFL
Investor and Media Contact: Director, Communications Targeted Genetics Corporation TARGETED GENETICS ANNOUNCES PRELIMINARY RESULTS OF PHASE I CLINICAL TRIAL OF tgAAC94 IN PATIENTS WITH INFLAMMATORY ARTHRITIS Results demonstrate safety and support continued study of tgAAC94 i
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics 206.521.7392 TARGETED GENETICS REPORTS FIRST QUARTER 2005 FINANCIAL RESULTS Seattle, WA
Investor and Media Contact: Director, Communications TARGETED GENETICS REPORTS FIRST QUARTER 2005 FINANCIAL RESULTS Seattle, WA April 26, 2004 Targeted Genetics Corporation (NASDAQ: TGEN) today announced its financial results for the first quarter of 2005. As previously annou
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS ANNOUNCES PRELIMINARY RESULTS FROM ITS PHASE II TRIAL OF tgAAVCF IN CYSTIC FIBROSIS Seat
Investor and Media Contact: Director, Communications Targeted Genetics Corporation ANNOUNCES PRELIMINARY RESULTS FROM ITS PHASE II TRIAL OF tgAAVCF IN CYSTIC FIBROSIS Seattle, WA March 17, 2005 Targeted Genetics Corporation (Nasdaq: TGEN) today reported that its Phase II cl
Read more →ARMPInvestor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 TARGETED GENETICS REPORTS FOURTH QUARTER AND YEAR-END 2004 FINANCIAL RESULTS Seattle, WA
Investor and Media Contact: Director, Communications Targeted Genetics Corporation TARGETED GENETICS REPORTS FOURTH QUARTER AND YEAR-END 2004 FINANCIAL RESULTS Seattle, WA March 3, 2005 Targeted Genetics Corporation (NASDAQ: TGEN) today announced its financial results for t
Read more →ARMPTargeted Genetics Corporation Stacie Byars 206-660-2588 TARGETED GENETICS ANNOUNCES PRELIMINARY SAFETY DATA FROM PHASE I HIV VACCINE TRIAL Seattle, WA
Targeted Genetics Corporation TARGETED GENETICS ANNOUNCES PRELIMINARY SAFETY DATA FROM PHASE I HIV VACCINE TRIAL Seattle, WA February 22, 2005 Targeted Genetics Corp. (Nasdaq: TGEN) today reported preliminary results from a Phase I trial of tgAAC09, an investigational recombin
Read more →ARMPTargeted Genetics Corporation Stephanie Seiler (206) 713-0124 TARGETED GENETICS AND CELLADON ANNOUNCE A COLLABORATION TO DEVELOP AAV-BASED GENE THERAPIES FOR CONGESTIVE HEART FAILURE - Deal terms include $6 mill
Targeted Genetics Corporation TARGETED GENETICS AND CELLADON ANNOUNCE A COLLABORATION TO DEVELOP AAV-BASED GENE THERAPIES FOR CONGESTIVE HEART FAILURE -Deal terms include $6 million equity investment in Targeted Genetics by Celladon s lead Seattle, WA and La Jolla, CA Januar
Read more →ARMPTargeted Genetics Corporation Courtney Self 206.521.7392 TARGETED GENETICS REPORTS THIRD QUARTER 2004 FINANCIAL RESULTS - Clinical Programs Remain on Track; Results Expected in First Half of 2005 - Seattle, WA
Targeted Genetics Corporation TARGETED GENETICS REPORTS THIRD QUARTER 2004 - Clinical Programs Remain on Track; Results Expected in First Half of 2005 - Seattle, WA November 4, 2004 Targeted Genetics Corporation (NASDAQ: TGEN) today announced its financial results for the thi
Read more →Competitive Position
How ARMP ranks across every disease it competes inCompetitive Position is a premium feature
See how ARMP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial